Glutamate Decarboxylase 1 Overexpression as a Poor Prognostic Factor in Patients with Nasopharyngeal Carcinoma

doi:10.7150/jca.15667

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/31002

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/31002

Title:	Glutamate Decarboxylase 1 Overexpression as a Poor Prognostic Factor in Patients with Nasopharyngeal Carcinoma
Authors:	Lee, Yi-Ying Chao, Tung-Bo Sheu, Ming-Jen Tian, Yu-Feng Chen, Tzu-Ju Lee, Sung-Wei He, Hong-Lin Chang, I-Wei Hsing, Chung-Hsi Lin, Ching-Yih Li, Chien-Feng
Contributors:	Chi Mei Med Ctr, Dept Pathol Yuans Gen Hosp, Dept Colorectal Surg Meiho Univ, Dept Hlth Business Adm Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol Chi Mei Med Ctr, Div Gen Surg Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr Chi Mei Med Ctr, Dept Pathol Chi Mei Med Ctr, Dept Radiat Oncol I Shou Univ, E DA Hosp, Dept Pathol Kaohsiung Chang Gung Mem Hosp, Dept Anesthesiol Chang Gung Univ, Coll Med Southern Taiwan Univ Sci & Technol, Dept Leisure Recreat & Tourism Management
Keywords:	GAD1 nasopharyngeal carcinoma glutamate acid decarboxylase 1 gamma-aminobutyric acid transcriptome Prognosis metastasis
Date:	2016
Issue Date:	2018-01-18 11:39:36 (UTC+8)
Publisher:	Ivyspring Int Publ
Abstract:	Background: Glutamate decarboxylase 1 (GAD1) which serves as a rate-limiting enzyme involving in the production of.-aminobutyric acid (GABA), exists in the GABAergic neurons in the central nervous system (CNS). Little is known about the relevance of GAD1 to nasopharyngeal carcinoma (NPC). Through data mining on a data set derived from a published transcriptome database, this study first identified GAD1 as a differentially upregulated gene in NPC. We aimed to evaluate GAD1 expression and its prognostic effect on patients with early and locoregionally advanced NPC. Methods: We evaluated GAD1 immunohistochemistry and performed an H-score analysis on biopsy specimens from 124 patients with nonmetastasized NPC receiving treatment. GAD1 overexpression was defined as an H score higher than the median value. The findings of such an analysis are correlated with clinicopathological behaviors and survival rates, namely disease-specific survival (DSS), distant-metastasis-free survival (DMeFS), and local recurrence-free survival (LRFS) rates. Results: GAD1 overexpression was significantly associated with an increase in the primary tumor status (p < 0.001) and American Joint Committee on Cancer (AJCC) stages III-IV (p = 0.002) and was a univariate predictor of adverse outcomes of DSS (p = 0.002), DMeFS (p < 0.0001), and LRFS (p = 0.001). In the multivariate comparison, in addition to advanced AJCC stages III-IV, GAD1 overexpression remained an independent prognosticator of short DSS (p = 0.004, hazard ratio = 2.234), DMeFS (p < 0.001, hazard ratio = 4.218), and LRFS (p = 0.013, hazard ratio = 2.441) rates. Conclusions: Our data reveal that GAD1 overexpression was correlated with advanced disease status and may thus be a critical prognostic indicator of poor outcomes in NPC and a potential therapeutic target to facilitate the development of effective treatment modalities.
Relation:	Journal of Cancer, v.7 n.12, pp.1716-1723
Appears in Collections:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1211	View/Open

Loading...